Info about some of Our Current Studies
Click the sections below to see more information about current studies that are open and enrolling new participants.
-
The purpose of this study is to see whether a hepatitis B vaccine called HEPLISAV-B is more effective in adults living with HIV than the current standard hepatitis B vaccine called ENGERIX-B. Vaccine side effects will also be studied.
Some participants in the study will receive a two-dose series of the HEPLISAV-B vaccine (the dosing approved by the FDA), and others will receive a three-dose series (an investigational dosing schedule).
To learn more about this study, email the research nurse: Tracey Watkins, LPN (tracey.d.watkins@vumc.org).
-
The purpose of this study is to see whether people living with HIV who gained a significant amount of weight after starting an ART regimen could gain less weight or lose weight after switching ART medicines.
People who sign up for this study have to currently be taking an ART regimen that includes an integrase strand transfer inhibitor (INSTI) and tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC).
The study will also see if a switching ART leads to differences in metabolic conditions (how the body stores and uses energy), cardiovascular health (the heart and blood vessels), and bone health.
To learn more about this study, email the research nurse: Morgan Lima, RN (morgan.c.shearer@vumc.org).
-
This study will see if long-acting injectable HIV medicine (a shot) can be used by people who have had problems taking their HIV pills regularly or have had problems attending their clinic appointments.
Only people with a detectable viral load can go on this study.
This study doesn't give the shot at the beginning. The first step is to take oral medicines for HIV and to lower the amount of virus in the blood.
After several months, people who sign up for this study will transition from pills to the shot.
To learn more about this study, email the research nurse: Tracey Watkins, LPN (tracey.d.watkins@vumc.org).
-
This study will help understand how HIV treatment affects body weight, body fat, and muscle mass.
This study is looking for 129 people in Nashville- especially people who haven't started HIV meds yet.
To learn more about this study, email the research nurse: Anna Tate, RN (anna.f.tate@vumc.org).
-
The goal of ENDEAVOR is to find a way to prevent throat cancer.
To learn more about this study, email the research nurse: Morgan Lima, RN (morgan.c.shearer@vumc.org).
-
This study is testing a medication used to treat cytomegalovirus (CMV). CMV is a virus that's very common in the US and usually doesn't cause problems. It's possible that some of the complications related to HIV could be related to also having CMV. This study will test whether treating CMV is beneficial.
To learn more about this study, email the research nurse: Joan Gottesman, RN (joan.gottesman@vumc.org).
